Milestone Pharmaceuticals Faces FDA Regulatory Risks, Stock Target Suggests High Upside

Milestone Pharmaceuticals (MIST) is navigating potential operational delays stemming from regulatory scrutiny, according to a recent disclosure. The company highlights the risk of slowed review and approval timelines for its product candidates due to disruptions at the Food and Drug Administration (FDA), the Securities and Exchange Commission (SEC), and similar foreign regulatory bodies.

Regulatory Risks and Potential Impacts

Milestone Pharmaceuticals acknowledges that political gridlock, agency funding shortages, staffing gaps, and even government shutdowns could impair the ability of these regulatory authorities to function effectively. These impairments could directly impact the company’s development and commercialization plans, potentially leading to adverse business consequences. The company is based in Montréal, Québec, Canada and was incorporated in July 2003.

Cardamyst Approval and Executive Compensation

Recent equity events tied to the FDA approval of Cardamyst (etripamil) have been reported. Muller Lorenz, Milestone’s Chief Commercial Officer (CCO), saw 100,000 performance stock units (PSUs) vest upon receiving the New Drug Application Approval Letter for Cardamyst on December 12, 2025. Lorenz was granted 100,000 stock options with an exercise price of $1.74, vesting in two installments on June 12, 2026, and December 12, 2026.

Further equity activity included the conversion of 20,100 restricted stock units (RSUs) into common shares on January 26, 2026, as part of an award vesting over four years. Lorenz sold shares to cover tax liabilities from the vesting of PSUs and RSUs.

Stock Price Target and Financial Results

Despite the regulatory risks, the average MIST stock price target is $8.00, suggesting a potential upside of 488.24%. Milestone Pharmaceuticals announced its financial results for the fourth quarter and fiscal year ended December 31, 2025, on March 20, 2026. Investors can find more detailed information about the company’s risk factors and financial filings on the Milestone Pharmaceuticals Investor Relations website.